Arrowstreet Capital Limited Partnership bought a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 120,670 shares of the company's stock, valued at approximately $5,372,000. Arrowstreet Capital Limited Partnership owned 0.26% of Omnicell at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in the business. EntryPoint Capital LLC bought a new stake in shares of Omnicell during the fourth quarter valued at approximately $244,000. Segall Bryant & Hamill LLC purchased a new position in Omnicell during the fourth quarter valued at $649,000. Prudential Financial Inc. increased its holdings in Omnicell by 26.4% in the 4th quarter. Prudential Financial Inc. now owns 231,053 shares of the company's stock valued at $10,286,000 after acquiring an additional 48,193 shares during the last quarter. Advantage Alpha Capital Partners LP lifted its stake in Omnicell by 14.9% in the 4th quarter. Advantage Alpha Capital Partners LP now owns 52,041 shares of the company's stock worth $2,317,000 after purchasing an additional 6,753 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Omnicell by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock valued at $247,628,000 after purchasing an additional 28,573 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.
Omnicell Trading Up 0.4 %
Shares of OMCL stock traded up $0.11 during trading hours on Friday, reaching $31.19. 566,792 shares of the stock were exchanged, compared to its average volume of 529,211. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of 115.52, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.75. The company's 50-day moving average price is $36.34 and its 200-day moving average price is $41.68. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13.
Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, equities analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the company. Benchmark reiterated a "buy" rating and issued a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. JPMorgan Chase & Co. decreased their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, March 20th. StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a research report on Monday, March 24th. Wells Fargo & Company reduced their price target on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, Bank of America lowered their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research report on Monday, January 6th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $51.00.
Check Out Our Latest Analysis on OMCL
About Omnicell
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Read More
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
